MX2018014846A - Composiciones antineoplasicas. - Google Patents
Composiciones antineoplasicas.Info
- Publication number
- MX2018014846A MX2018014846A MX2018014846A MX2018014846A MX2018014846A MX 2018014846 A MX2018014846 A MX 2018014846A MX 2018014846 A MX2018014846 A MX 2018014846A MX 2018014846 A MX2018014846 A MX 2018014846A MX 2018014846 A MX2018014846 A MX 2018014846A
- Authority
- MX
- Mexico
- Prior art keywords
- prostate cancer
- arn
- resistant prostate
- metastatic castration
- meth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000001093 anti-cancer Effects 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 6
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 abstract 3
- 229960004103 abiraterone acetate Drugs 0.000 abstract 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 abstract 2
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 230000001394 metastastic effect Effects 0.000 abstract 2
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 229920000193 polymethacrylate Polymers 0.000 abstract 2
- 239000007962 solid dispersion Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229960000853 abiraterone Drugs 0.000 abstract 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 abstract 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 230000000683 nonmetastatic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulaciones farmaceuticas de acetato de abiraterona y ARN-509, que se pueden administrar a mamiferos, en particular a humanos, que sufren de una enfermedad o afeccion relacionada con un receptor androgenico (AR), en particular, cancer, mas particularmente, cancer de prostata, que incluye entre otros, cancer de prostata resistente a la castracion, cancer de prostata metastasico resistente a la castracion, cancer de prostata metastasico resistente a la castracion en pacientes que no han recibido quimioterapia, cancer de prostata sensible a hormonas recidivantes bioquimicamente o cancer de prostata no metastasico resistente a la castracion de alto riesgo; en un aspecto, estas formulaciones comprenden acetato de abiraterona y una dispersion solida de ARN- 509 y un polimero seleccionado entre HPMCAS, un copolimero de poli(meta)acrilato y mezclas de estos; en un aspecto, estas formulaciones comprenden un granulado de acetato de abiraterona y una dispersion solida de ARN-509 y un polimero seleccionado entre HPMCAS, un copolimero de poli(meta)acrilato y mezclas de estos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172968 | 2016-06-03 | ||
| PCT/US2017/032815 WO2017209939A1 (en) | 2016-06-03 | 2017-05-16 | Anticancer compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014846A true MX2018014846A (es) | 2019-03-14 |
Family
ID=56148120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014846A MX2018014846A (es) | 2016-06-03 | 2017-05-16 | Composiciones antineoplasicas. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190216829A1 (es) |
| EP (1) | EP3463377A1 (es) |
| JP (1) | JP2019517497A (es) |
| KR (1) | KR20190015314A (es) |
| CN (1) | CN109219437A (es) |
| AR (1) | AR108489A1 (es) |
| AU (1) | AU2017275396A1 (es) |
| BR (1) | BR112018074965A2 (es) |
| CA (1) | CA3024872A1 (es) |
| CL (1) | CL2018003403A1 (es) |
| CO (1) | CO2018012857A2 (es) |
| CR (1) | CR20180600A (es) |
| EA (1) | EA201892828A1 (es) |
| IL (1) | IL263157A (es) |
| MA (1) | MA45090A (es) |
| MX (1) | MX2018014846A (es) |
| NI (1) | NI201800127A (es) |
| PE (1) | PE20181925A1 (es) |
| PH (1) | PH12018502334A1 (es) |
| SG (1) | SG11201809680QA (es) |
| TN (1) | TN2018000366A1 (es) |
| TW (1) | TW201808287A (es) |
| UA (1) | UA124154C2 (es) |
| WO (1) | WO2017209939A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114886852A (zh) | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | 抗癌组合物 |
| JP6830892B2 (ja) * | 2014-12-05 | 2021-02-17 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 抗癌性組成物 |
| CZ2016573A3 (cs) | 2016-09-16 | 2018-03-28 | Zentiva, K.S. | Pevná formulace abirateronu acetátu vyráběná technologií fluidní granulace |
| CN109125276A (zh) * | 2017-06-19 | 2019-01-04 | 齐鲁制药有限公司 | 一种醋酸阿比特龙片剂的药物组合物及其制备方法 |
| WO2019155416A2 (en) * | 2018-02-09 | 2019-08-15 | Kashiv Pharma Llc | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens |
| EP3784218A1 (en) | 2018-04-26 | 2021-03-03 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
| US12403149B2 (en) | 2019-07-15 | 2025-09-02 | Shilpa Medicare Limited | Dispersible tablets of abiraterone acetate |
| JP2022091129A (ja) * | 2020-12-08 | 2022-06-20 | 東和薬品株式会社 | 組成物ならびにその製造方法および用途 |
| WO2025174375A1 (en) * | 2024-02-15 | 2025-08-21 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020097A1 (en) | 1992-03-31 | 1993-10-14 | British Technology Group Ltd. | 17-substituted steroids useful in cancer treatment |
| JP6182209B2 (ja) | 2012-06-07 | 2017-08-16 | アラゴン ファーマシューティカルズ，インコーポレイテッド | アンドロゲン受容体変調剤の結晶質形態 |
| KR20180021932A (ko) * | 2013-03-15 | 2018-03-05 | 아이슈티카 인코포레이티드 | 아비라테론 아세테이트 제제 |
| MX386859B (es) * | 2014-02-05 | 2025-03-19 | Lek Pharmaceuticals | Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos. |
| TWI803187B (zh) * | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
-
2017
- 2017-05-16 AR ARP170101300A patent/AR108489A1/es unknown
- 2017-05-16 UA UAA201813020A patent/UA124154C2/uk unknown
- 2017-05-16 SG SG11201809680QA patent/SG11201809680QA/en unknown
- 2017-05-16 EA EA201892828A patent/EA201892828A1/ru unknown
- 2017-05-16 KR KR1020187036312A patent/KR20190015314A/ko not_active Ceased
- 2017-05-16 CR CR20180600A patent/CR20180600A/es unknown
- 2017-05-16 WO PCT/US2017/032815 patent/WO2017209939A1/en not_active Ceased
- 2017-05-16 BR BR112018074965-6A patent/BR112018074965A2/pt not_active Application Discontinuation
- 2017-05-16 MA MA045090A patent/MA45090A/fr unknown
- 2017-05-16 TW TW106116122A patent/TW201808287A/zh unknown
- 2017-05-16 JP JP2018562674A patent/JP2019517497A/ja active Pending
- 2017-05-16 MX MX2018014846A patent/MX2018014846A/es unknown
- 2017-05-16 CN CN201780034086.1A patent/CN109219437A/zh active Pending
- 2017-05-16 TN TNP/2018/000366A patent/TN2018000366A1/en unknown
- 2017-05-16 PE PE2018003138A patent/PE20181925A1/es unknown
- 2017-05-16 CA CA3024872A patent/CA3024872A1/en not_active Abandoned
- 2017-05-16 EP EP17725489.3A patent/EP3463377A1/en not_active Withdrawn
- 2017-05-16 US US16/306,802 patent/US20190216829A1/en not_active Abandoned
- 2017-05-16 AU AU2017275396A patent/AU2017275396A1/en not_active Abandoned
-
2018
- 2018-11-06 PH PH12018502334A patent/PH12018502334A1/en unknown
- 2018-11-20 IL IL263157A patent/IL263157A/en unknown
- 2018-11-27 CO CONC2018/0012857A patent/CO2018012857A2/es unknown
- 2018-11-29 CL CL2018003403A patent/CL2018003403A1/es unknown
- 2018-11-30 NI NI201800127A patent/NI201800127A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190015314A (ko) | 2019-02-13 |
| US20190216829A1 (en) | 2019-07-18 |
| PE20181925A1 (es) | 2018-12-11 |
| BR112018074965A2 (pt) | 2019-03-12 |
| PH12018502334A1 (en) | 2019-07-29 |
| NI201800127A (es) | 2019-03-29 |
| SG11201809680QA (en) | 2018-11-29 |
| WO2017209939A1 (en) | 2017-12-07 |
| CL2018003403A1 (es) | 2019-02-01 |
| TN2018000366A1 (en) | 2020-06-15 |
| AU2017275396A1 (en) | 2018-11-22 |
| CR20180600A (es) | 2019-07-11 |
| CA3024872A1 (en) | 2017-12-07 |
| UA124154C2 (uk) | 2021-07-28 |
| CN109219437A (zh) | 2019-01-15 |
| EP3463377A1 (en) | 2019-04-10 |
| CO2018012857A2 (es) | 2018-12-14 |
| JP2019517497A (ja) | 2019-06-24 |
| EA201892828A1 (ru) | 2019-05-31 |
| MA45090A (fr) | 2021-04-28 |
| IL263157A (en) | 2018-12-31 |
| AR108489A1 (es) | 2018-08-29 |
| TW201808287A (zh) | 2018-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502334A1 (en) | Anticancer compositions | |
| PH12017500979A1 (en) | Anticancer compositions | |
| MX384382B (es) | Composiciones anticancerígenas. | |
| MX2021013965A (es) | Composiciones anticancerigenas. | |
| ZA202501583B (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| PH12017500023A1 (en) | Targeted conjugates and particles and formulations thereof | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| JO3606B1 (ar) | معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| PH12017502392A1 (en) | Targeted conjugates and particles and formulations thereof | |
| MX2020007559A (es) | Formulaciones farmaceuticas. | |
| TH170798A (th) | องค์ประกอบต้านมะเร็ง | |
| He et al. | Update of the most recent advances in the treatment of metastatic castration-resistant prostate cancer |